Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on EW stock, giving a Buy rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Anthony Petrone has given his Buy rating due to a combination of factors that highlight Edwards Lifesciences’ promising growth trajectory. Notably, the company has demonstrated strong performance in both its Transcatheter Mitral and Tricuspid Therapies (TMTT) and its core Transcatheter Aortic Valve Replacement (TAVR) segments, with significant revenue beats that exceeded expectations. The TMTT segment is gaining momentum, particularly with the Pascal device capturing more market share in the US, while the TAVR segment’s stable outlook is bolstered by potential increases in asymptomatic patient volumes.
Furthermore, Petrone sees future catalysts that could accelerate growth, including the anticipated national coverage determination for Evoque in tricuspid replacement and expected guideline changes that may expand TAVR’s addressable market. These developments support confidence in achieving long-range plan targets through 2030. Consequently, Edwards Lifesciences remains an attractive growth opportunity within the medical technology sector, justifying the Buy rating maintained by Mizuho Securities.
In another report released yesterday, Barclays also reiterated a Buy rating on the stock with a $90.00 price target.
Based on the recent corporate insider activity of 126 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year.